Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …

Clinical and epidemiologic research has focused on the identification of risk factors that may
be modified in predementia syndromes, at a preclinical and early clinical stage of …

Preventing or postponing the onset of Alzheimer’s disease (AD) and delaying or slowing its
progression would lead to a consequent improvement of health status and quality of life in …

In the last decade, the association between diet and cognitive function or dementia has
been largely investigated. In the present article, we systematically reviewed observational …

Several epidemiological studies suggest that long-term use of non-steroidal anti-inflammatory
drugs (NSAIDs) may protect subjects carrying one or more ε4 allele of the apolipoprotein …

Neuroinflammation commences decades before Alzheimer's disease (AD) clinical onset and
represents one of the earliest pathomechanistic alterations throughout the AD continuum. …

According to the β-amyloid (Aβ) hypothesis, compounds that inhibit or modulate γ secretase,
the pivotal enzyme that generates Aβ, are potential therapeutics for Alzheimer's disease (AD…

Recent prospective studies provided evidence that higher adherence to a Mediterranean-type
diet could be associated with slower cognitive decline, reduced risk of progression from …

The failure of several Phase II/III clinical trials in Alzheimer’s disease (AD) with drugs targeting
β-amyloid accumulation in the brain fuelled an increasing interest in alternative treatments …

Objective: In several longitudinal studies, light‐to‐moderate drinking of alcoholic beverages
has been proposed as being protective against the development of age‐related changes in …